Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts

M. Frueh; C. M. Panje; M. Reck; F. Blackhall; R. Califano; F. Cappuzzo; B. Besse; S. Novello; P. Garrido; E. Felip; M. O'Brien; L. Paz Ares; F. de Marinis; Virginie Westeel; D. De Ruysscher; P. M. Putora

doi:10.1016/j.lungcan.2020.03.024

Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts

M. Frueh^*, C. M. Panje, M. Reck, F. Blackhall, R. Califano, F. Cappuzzo, B. Besse, S. Novello, P. Garrido, E. Felip, M. O'Brien, L. Paz Ares, F. de Marinis, Virginie Westeel, D. De Ruysscher, P. M. Putora

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	6-11
Number of pages	6
Journal	Lung Cancer
Volume	146
DOIs	https://doi.org/10.1016/j.lungcan.2020.03.024
Publication status	Published - Aug 2020

Keywords

Small cell lung cancer (SCLC)
Second-line chemotherapy
Decision making
Objective consensus
OPEN-LABEL
PHASE-III
TOPOTECAN
CHEMOTHERAPY
MULTICENTER
RECHALLENGE
ETOPOSIDE
SELECTION
OUTCOMES
IASLC

Access to Document

10.1016/j.lungcan.2020.03.024

Cite this

Frueh, M., Panje, C. M., Reck, M., Blackhall, F., Califano, R., Cappuzzo, F., Besse, B., Novello, S., Garrido, P., Felip, E., O'Brien, M., Ares, L. P., de Marinis, F., Westeel, V., De Ruysscher, D., & Putora, P. M. (2020). Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts. Lung Cancer, 146, 6-11. https://doi.org/10.1016/j.lungcan.2020.03.024

Frueh, M. ; Panje, C. M. ; Reck, M. ; Blackhall, F. ; Califano, R. ; Cappuzzo, F. ; Besse, B. ; Novello, S. ; Garrido, P. ; Felip, E. ; O'Brien, M. ; Ares, L. Paz ; de Marinis, F. ; Westeel, Virginie ; De Ruysscher, D. ; Putora, P. M. / Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts. In: Lung Cancer. 2020 ; Vol. 146. pp. 6-11.

@article{8ed2c981c41a4e939ca25563712f7ed3,

title = "Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts",

keywords = "Small cell lung cancer (SCLC), Second-line chemotherapy, Decision making, Objective consensus, OPEN-LABEL, PHASE-III, TOPOTECAN, CHEMOTHERAPY, MULTICENTER, RECHALLENGE, ETOPOSIDE, SELECTION, OUTCOMES, IASLC",

author = "M. Frueh and Panje, {C. M.} and M. Reck and F. Blackhall and R. Califano and F. Cappuzzo and B. Besse and S. Novello and P. Garrido and E. Felip and M. O'Brien and Ares, {L. Paz} and {de Marinis}, F. and Virginie Westeel and {De Ruysscher}, D. and Putora, {P. M.}",

year = "2020",

month = aug,

doi = "10.1016/j.lungcan.2020.03.024",

language = "English",

volume = "146",

pages = "6--11",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

}

Frueh, M, Panje, CM, Reck, M, Blackhall, F, Califano, R, Cappuzzo, F, Besse, B, Novello, S, Garrido, P, Felip, E, O'Brien, M, Ares, LP, de Marinis, F, Westeel, V, De Ruysscher, D & Putora, PM 2020, 'Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts', Lung Cancer, vol. 146, pp. 6-11. https://doi.org/10.1016/j.lungcan.2020.03.024

Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts. / Frueh, M.; Panje, C. M.; Reck, M.; Blackhall, F.; Califano, R.; Cappuzzo, F.; Besse, B.; Novello, S.; Garrido, P.; Felip, E.; O'Brien, M.; Ares, L. Paz; de Marinis, F.; Westeel, Virginie; De Ruysscher, D.; Putora, P. M.

In: Lung Cancer, Vol. 146, 08.2020, p. 6-11.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts

AU - Frueh, M.

AU - Panje, C. M.

AU - Reck, M.

AU - Blackhall, F.

AU - Califano, R.

AU - Cappuzzo, F.

AU - Besse, B.

AU - Novello, S.

AU - Garrido, P.

AU - Felip, E.

AU - O'Brien, M.

AU - Ares, L. Paz

AU - de Marinis, F.

AU - Westeel, Virginie

AU - De Ruysscher, D.

AU - Putora, P. M.

PY - 2020/8

Y1 - 2020/8

KW - Small cell lung cancer (SCLC)

KW - Second-line chemotherapy

KW - Decision making

KW - Objective consensus

KW - OPEN-LABEL

KW - PHASE-III

KW - TOPOTECAN

KW - CHEMOTHERAPY

KW - MULTICENTER

KW - RECHALLENGE

KW - ETOPOSIDE

KW - SELECTION

KW - OUTCOMES

KW - IASLC

U2 - 10.1016/j.lungcan.2020.03.024

DO - 10.1016/j.lungcan.2020.03.024

M3 - Article

C2 - 32485661

VL - 146

SP - 6

EP - 11

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -